Ramachandran Jeyamani
Department of Hepatology, Christian Medical College, Vellore, Tamil Nadu, India.
J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S50-6. doi: 10.1016/j.jceh.2014.03.050. Epub 2014 Apr 21.
Hepatocellular carcinoma (HCC) is a dreaded complication of cirrhosis as it is the commonest cause of mortality in these patients. The last few years have seen a dramatic improvement in the management of this tumor as nearly 50-70% of selected patients with early HCC survive for a median period of up to 5 years after liver transplantation, resection or local ablation. Surveillance has been found to be an effective tool to detect early tumors and expand the applicability of these curative treatment options. Semiannual ultrasonogram is recommended for surveillance by the American, European and Asia Pacific liver societies and is the standard of care in many countries. There is increasing evidence that this practice improves survival too. Since the only way to improve the outlook of HCC is its diagnosis prior to commencement of symptoms, providing surveillance becomes a major responsibility of physicians caring for patients with chronic liver disease. This review attempts to discuss the population at risk of HCC, modalities and frequency of surveillance tests, cost effectiveness and also the logistics of its delivery in the Indian context.
肝细胞癌(HCC)是肝硬化令人恐惧的并发症,因为它是这些患者最常见的死亡原因。在过去几年中,这种肿瘤的治疗有了显著改善,因为近50%-70%经过挑选的早期HCC患者在肝移植、切除或局部消融后存活时间中位数可达5年。监测已被证明是检测早期肿瘤并扩大这些治愈性治疗方案适用性的有效工具。美国、欧洲和亚太地区肝脏学会推荐每半年进行一次超声检查用于监测,这也是许多国家的标准治疗方法。越来越多的证据表明这种做法也能提高生存率。由于改善HCC预后的唯一方法是在症状出现之前进行诊断,因此提供监测成为照顾慢性肝病患者的医生的一项主要责任。本综述试图讨论HCC的高危人群、监测检查的方式和频率、成本效益以及在印度背景下实施监测的后勤保障。